A session dedicated to "Accurate Mass LC-MS Approaches for Characterization and Quantification of Drugs and Metabolites" will kick off the fourth day of the technical program on Tuesday at the 57th ASMS Conference in Philadelphia, Pennsylvania.
A session dedicated to “Accurate Mass LC-MS Approaches for Characterization and Quantification of Drugs and Metabolites” will kick off the fourth day of the technical program on Tuesday at the 57th ASMS Conference in Philadelphia, Pennsylvania.
The oral session will begin at 8:30 a.m. with a group from Bristol-Myers Squibb giving a talk on the “Identification of a novel CYP1A2-mediated bioactivation pathway of nimesulide using LTQ-Orbitrap and Q-trap mass spectrometers.”
Li Ma, Qian Ruan, Jinping Gan, W. Griffith Humphreys, and Mingshe Zhu’s presentation will focus on “identification of a novel reactive intermediate derived from oxidative metabolism of nimesulide and the CYP enzyme responsible for the bioactivation.”
Five more presentations will follow the Bristol-Myers Squibb group, with topics ranging from the “Combination of Fast Liquid Chromatography and Quadrupole Time-of-Flight for Quantitative Analysis of Pharmaceuticals in Plasma using Accurate Mass” to “2D mass mapping: novel data visualization method for complex peptide mixtures analysis.”
Wrapping up the morning session will be Olaf Boernsen, Denis Herzog, Stephan Charmont, Nelson Guerreiro, Francois Legay, and Stephan Bek, all from Novartis Pharma AG, Basel, Switzerland. Their talk will be on “Method Development for Absolute Quantitation of Insulin Grows Factor Binding Proteins (IGFBP) in Plasma Samples by Capillary LC-MS.” They will zero in on “Multiplex absolute quantitative MRM assay with increased sensitivity by using sample pretreatment steps and selection of unique peptide transitions.”